Background: Previous studies suggest that infection with non-R5-tropic subtype B HIV-1, compared with R5, is associated with a more rapid decline in CD4 þ cell count, but does not affect PI/(N)NRTI therapy outcome. Here, we explored clinical correlates associated with viral tropism in subtype A1 and D infections.
Introduction
HIV is genetically diverse. Subtype B HIV-1 is the most prevalent strain in Europe and North America; however, infection by this subtype accounts for just above 12% of the global epidemic [1] . Treatment-naive individuals infected with different HIV-1 subtypes has been shown to experience varying rates of disease progression, with subtype C and D described as being more aggressive with a faster disease progression [2, 3] . Another study showed that subtype D-infected individuals are more likely to fail antiretroviral therapy with drug resistance mutations than those infected with subtype A [4] .
Another facet of HIV genetic diversity that may impact virulence is viral tropism. HIV can be classified by its coreceptor usage: 'R5-tropic HIV' infects host cells that express cell surface C-C motif chemokine receptor 5 receptors, whereas strains that can use alternative coreceptors, including C-X-C motif chemokine receptor 4 are collectively termed 'non-R5-tropic HIV' [5, 6] . Detection of non-R5-tropic HIV virus is associated with lower CD4 þ cell counts [7, 8] , a more advanced disease stage and a faster disease progression, but there is no clear impact of coreceptor usage on antiretroviral therapy response [9] . In a predominantly subtype B chronically infected cohort, non-R5-tropic HIV-1 was associated with a poorer pretherapy baseline viral load and CD4 þ cell count, but tropism was not associated with therapy outcomes examined, including time to virologic suppression, time to virologic rebound, time to CD4 þ decline and time to nonaccidental death [10] . It has not been reported whether the same trends could be observed in other HIV-1 subtypes.
The relationship between HIV-1 subtype, tropism, and their associations with clinical correlates is also poorly understood. Both subtype D and non-R5 are independently associated with a faster disease progression [2, 3, 7, 8] . Numerous studies have shown that subtype D viruses are more likely to be non-R5-tropic [7, 8, [11] [12] [13] [14] , and non-R5-tropic subtype D infections in Ugandan babies is linked to higher mortality [12] . These observations lead to the question of whether an infection that is both subtype D and non-R5 would lead to synergistic increase in disease progression. Little evidence exists to evaluate this hypothesis.
The objective of this study is to explore clinical correlates associated with viral tropism in subtype A1 and D HIV-1 infections. We hypothesize that in a Ugandan cohort in which subtype A1 and D HIV-1 cocirculate, having non-R5-tropic HIV-1 would be associated with a poorer pretherapy clinical profiles, but would not differ from R5-infections in therapy outcomes. HIV-1 gp41 and V3 sequences were used to infer viral subtype and genotypic tropism, respectively, which were then used to test for statistical associations against pre and posttreatment clinical correlates. We also compared between the subtypes and explored relationships between subtype, tropism, and clinical correlates.
Methods

Cohort description
The Uganda AIDS Rural Treatment Outcomes (UARTO study) is a cross-sectional cohort of 500 initially treatment-naive HIV-1-infected study participants followed primarily at the immune suppression syndrome Clinic in Mbarara, Uganda, a rural community 4.5 h by automobile from the capital city of Kampala [15] [16] [17] . Participants were enrolled just prior to the start of antiretroviral regimen between 27 June 2005 and 8 April 2010, and were longitudinally followed approximately every 3 months to receive HIV RNA and CD4 þ cell count monitoring for up to 7.5 years until 11 January 2013 or when they were lost to follow-up. Infections were predominantly subtype A1 (49%) and D (43%) [18] . All 500 participants were included in this study. Overall adherence for the cohort was 86% [19] . Mortality data, opportunistic infections, treatment side-effects, and reasons for loss to follow-up were unavailable. The study was approved by the Mbarara University of Science and Technology Human Subjects Committee (14/01-03), the Uganda Council of Science and Technology (HS 938), Partners Healthcare Human Subjects Committee (2011P000522), the University of British Columbia/ Providence Healthcare Research Ethics Board (H11-01642), and the University of California Human Research Subjects Committee (10-03457).
PCR and Sanger sequencing
Total nucleic acid was extracted from 500 ml of plasma samples using NucliSENS easyMag (bioMérieux). Reverse transcription and cDNA synthesis was performed for HIV-1 env V3 loop, protease/reverse transcriptase and gp41 independently with SuperScript III One-Step RT-PCR System (Invitrogen, Burlington, Ontario, Canada) followed by 'nested' second-round PCR ( Supplementary Tables 1 and 3 , http://links.lww. com/QAD/A921) (modified based on [20, 21] Table 2 , http:// links.lww.com/QAD/A921). Resulting chromatograms were aligned against HXB2 and base-called using in-house software RECall [22] .
Definitions of viral tropism and subtype
Viral tropism was inferred using geno2pheno (g2p) (http://coreceptor.geno2pheno.org/) [23] , a bioinformatics tool that compared user input HIV-1 env V3-loop nucleic acid sequences to known V3 sequences that had matching phenotypic tropism data. g2p gave one false positive rate (fpr) value between 0 and100% per input V3 sequence, representing its likelihood to be non-R5-tropic. In this study, a virus was inferred R5-tropic if g2p fpr was less than 5.75%, and non-R5-tropic if g2p fpr was at least 5.75%. This cutoff value was chosen for our primary analysis to infer tropism because it has been shown to predict non-B HIV-1 phenotypic tropism results with similar sensitivity and specificity compared with subtype B viruses [24] . HIV-1 subtype was inferred using HIV-1 env gp41 sequences and RIP 3.0 (http://www.hiv.lanl.gov/ content/sequence/RIP/RIP.html) with a window size of 400 and confidence interval (CI) of 95%. V3 loop sequence alone ($105 nucleotides) was too short for RIP 3.0; therefore, gp41 ($1035 nucleotides) was chosen for subtype prediction because of its close proximity to V3 in the genome and its location in env. All intragene recombinants were excluded. Other definitions of viral tropism (g2p fpr cutoff 5, 10, 15, 20%, and PhenoSeq [25] ) and subtype (RIP using protease/reverse transcriptase, RIP with reduced window size of 100 and REGA, http://www.bioafrica.net/rega-genotype/html/subtypin ghiv.html) were examined as part of the sensitivity analysis.
Definitions of therapy outcomes
Virologic suppression was defined as less than 400 copies HIV RNA/ml to reflect the viral load detection limit during the initial years of the follow-up period. Four therapy outcomes were examined: time to virologic suppression (first of two consecutive viral load <400 copies HIV RNA/ml); time to virologic rebound (first of two consecutive viral load !400 copies HIV RNA/ml postsuppression); time to any CD4 þ decline below baseline; and time to CD4 þ recovery (first of two consecutive posttherapy CD4 þ cell count increase of >200 cells/ml from pretherapy count, or first of two consecutive posttherapy CD4 þ cell count >350 cells/ml). Other definitions of virologic suppression (50 and 500 copies HIV RNA/ml) and CD4 þ recovery (time to first of two consecutive posttherapy CD4 þ cell count above baseline) were examined as part of the sensitivity analysis.
Statistical methods
All statistical analyses were performed using R and/or GraphPad Prism 5.0. Two-tailed Mann-Whitney tests were used to compare pretherapy viral load, pretherapy CD4 þ cell count, g2p %fpr, and time to loss to follow-up. Log-rank tests were used to compare Kaplan-Meier curves of time to virologic suppression, postsuppression virologic rebound, CD4 þ decline, and CD4 þ recovery. Two-tailed Fisher's exact test was used to compare the prevalence of dichotomized non-R5 and R5 in subtype A1 and D.
A multivariable linear regression was used to explore the effect of viral subtype, viral tropism, sex, age, and baseline viral load on baseline CD4 þ cell count. In this analysis, the square root of baseline CD4 þ cell count was used to obtain normality as previously described [16, 17] ; normality of the transformed data were confirmed by Q-Q plot. CI at 95% for each coefficient are reported in the result section as CI: (lower, upper).
Statistical significance was defined as P less than 0.05. Note, because of the large number of statistical tests performed in the sensitivity analyses, Bonferroni correction should arguably be used to adjust the threshold for statistical significance to P ¼ 0.05/470 ¼ 0.0001.
Results
Pretherapy baseline characteristics and overall therapy outcomes
Based on our definitions of viral subtype (RIP, gp41) and tropism (g2p 5.75%fpr cutoff, env V3), 339 of the 500 UARTO study participants were infected with subtype A1 or D HIV-1 and had an inferred V3 tropism result: 231 (68%) were women, and 196 (58%) were infected with subtype A1. Median age was 35 years (Q1-Q3 30-39), baseline viral load 1 Â 10 5 copies HIV RNA/ml (Q1-Q3 4 Â 10 4 -4 Â 10 5 ), and baseline CD4 þ cell count 129 cells/ml (Q1-Q3 70-202). Initial regimens were primarily nevirapine (86%) and efavirenz-based (12%) in combination with lamivudine and zidovudine as backbones.
Longitudinal viral load and CD4 þ data were available for n ¼ 315 of these patients: 94% achieved virologic suppression (defined as first of two consecutive viral load <400 copies HIV RNA/ml) within a median of 3 months posttherapy, 10% of those who achieved suppression experienced subsequent virologic rebound (defined as first of two consecutive viral load !400 copies HIV RNA/ml postsuppression) over a median of 1.4 years postsuppression, and 72% achieved CD4 þ recovery (first of two consecutive posttherapy CD4 þ cell count increase of >200 cells/ml from pretherapy count, or first of two consecutive posttherapy CD4 þ cell count >350 cells/ml) in a median of 2.2 years.
Primary analysis: clinical correlates of R5 vs. non-R5 infections
In subtype A1 infections, non-R5 (n ¼ 178) had significantly lower baseline CD4 þ cell count than R5 (n ¼ 18) (median 57 vs. 147 cells/ml, P ¼ 0.005). No other clinical correlates or outcomes tested was significantly different, including baseline viral load (P ¼ 0.3), time to virologic suppression (P ¼ 0.7), time to CD4 þ decline below baseline (P ¼ 0.2), and time to CD4 þ recovery (P ¼ 0.3) ( Fig. 1) .
In subtype D infections, the same pattern was observed: Non-R5 had lower baseline CD4 þ cell count than R5 (median 80 vs. 128 cells/ml, P ¼ 0.006). No other clinical correlates or outcomes tested was statistically different, including baseline viral load (P ¼ 0.4), time to virologic suppression (P ¼ 0.3), time to CD4 þ decline below baseline (P ¼ 0.5), and time to CD4 þ recovery (P ¼ 0.09) (Fig. 2) . Note that only two patients with non-R5 subtype A1 infections, and only one patient with non-R5 subtype D infection, experienced posttherapy virologic rebound over the course of maximum 7.5 years of longitudinal follow-up. As a result, statistical tests to compare time to virologic rebound between groups could not be performed because of the lack of statistical power.
To examine potential bias introduced by differences in loss to follow-up, we compared time to loss to follow-up between groups in all of the above 'time to event' analyses. We observed no significant differences between groups (all P > 0.1).
Secondary analysis: subtype A1 vs. D In addition to our primary analysis, we also observed that patients with subtype A1 viruses had significantly lower prevalence of non-R5 HIV-1 than those with subtype D (9 vs. 41%, P < 10 À11 ); this was in accordance with their striking difference in g2p %fpr distribution (median 64% fpr vs. 9% fpr, P < 10 À14 ) ( Fig. 3) . Furthermore, we observed that patients with subtype A1 infections had significantly higher baseline CD4 þ cell count than D (median 144 vs. 114 cells/ml, P ¼ 0.007); no other clinical correlates or outcomes tested were statistically significant (all P > 0.09). Median time to loss to follow-up was not 1784 AIDS 2016, Vol 30 No 11 10 6 Pre-therapy baseline viral load Based on the above observations, we hypothesized that this lower pretherapy baseline CD4 þ cell count observed in subtype D infections, compared with subtype A1, was driven by viral tropism and not by viral subtype. Indeed, baseline CD4 þ cell count in subtype A1 R5 and subtype D R5 HIV-1 infections were not statistically different (median 147 vs. 128 cells/ml, P ¼ 0.2). The same was true for subtype A1 vs. subtype D non-R5 HIV-1 infections (median 57 vs. 80 cells/ml, P ¼ 0.6). In a multivariable linear regression model with baseline CD4 þ cell count as the response variable, tropism was found to be a HIV-1 subtype A1 and D tropism and its clinical correlates Lee et al. 1785 10 6 Pre-therapy baseline viral load Viral load (copies HIV RNA/ml) significant predictor [CI: (À6 Â 10 À6 , À3 Â 10 À6 ), P < 10 À5 ] while controlling for sex [CI: (À0.03, 1.9), P ¼ 0.06], age [CI: (À0.01, 0.1), P ¼ 0.1], subtype [CI: (À1.7, 0.1), P ¼ 0.1], and baseline viral load [CI: (À3.7, À1.5), P < 10 À6 ). Subtype and the interaction between subtype and tropism were not found to be significant predictors of baseline CD4 þ cell count.
Sensitivity analyses
To evaluate the effect of using another part of the HIV genome for subtype prediction, protease/reverse transcriptase was chosen because it is arguably the most commonly sequenced part of the HIV genome globally because of genotypic resistance testing [26] . Among all pretherapy protease/reverse transcriptase sequences (n ¼ 454), 44% were subtype A1, and 37% were D. Absolute concordance between subtype predictions within a patient using protease/reverse transcriptase vs. gp41 to infer subtype was 66%, indicating a high prevalence of recombination in this cohort. Using this alternative subtype definition, a similar pattern was observed in both subtypes: non-R5 had lower baseline CD4 þ cell count than R5 infections (A: P ¼ 0.02; D: P ¼ 0.002); no other clinical correlates or outcomes tested were statistically different (all P > 0.08).
Sensitivity analyses were also performed to examine whether a different RIP window size (100), a different HIV-1 subtyping tool (REGA), a different and subtypespecific algorithm to infer viral tropism (PhenoSeq [25] ), different g2p fpr % cutoffs (5, 10, 15, and 20%), different definitions of virologic suppression (50 and 500 copies HIV RNA/ml), or a different measure of CD4 þ recovery (time to first of two consecutive posttherapy CD4 þ above baseline) would yield different observations. In summary, all yielded trends similar to our primary analysis regardless of HIV gene used to infer subtype, g2p fpr % cutoff values, and the definition of virologic suppression or CD4 þ recovery (results not shown).
Discussion
In summary, we found that in both subtype A1 and D infections, non-R5-tropic HIV-1 was associated with lower pretherapy baseline CD4 þ cell count, but not with pretherapy baseline viral load, nor with any of the posttherapy outcomes examined. Furthermore, we identified viral tropism as inferred from HIV-1 V3 sequence, but not subtype, as the apparent driver for the observed association between both non-R5 tropism and subtype D with a lower pretherapy baseline CD4 þ cell count.
Neither subtype nor tropism affected PI/(N)NRTI therapy outcomes in subtype A1 or D, R5 or non-R5 infections for an extended period of time. Overall, 94% of study participants achieved virologic suppression within 3 months posttherapy. We did not observe sufficient cases of posttherapy viral load rebound, to the extent that it was impossible to perform meaningful statistical tests even after 7.5 years of follow-up time. This implies that even if non-R5 tropism had led to an increased frequency of viral load rebound, the magnitude of its effect must be small. This finding is similar to previous findings in subtype B patients [10] . Together, our observations suggest that HIV care architecture was highly effective at least in this particular rural Ugandan cohort setting; specifically, the patients received frequent, 3-6 months apart clinical monitoring, and adherence was at a median of 86% [19] . However, it should also be noted that our conclusion is limited by the lack of mortality data; individuals who did not experience virologic rebound could either be lost to follow-up because of non-AIDS-related reasons, or could have died without a chance for us to observe two consecutive rise in viral load. To shed more light on the effect of this limitation, we compared time to loss to follow-up between the groups, but did not observe significant differences.
Another major question addressed by our study is the relationship between subtype, tropism, and pretherapy CD4 þ cell count. Previous studies tend to focus on only two of the three factors at a time: in terms of the relationship between HIV-1 subtype and pretherapy CD4 þ cell count, our observation agrees with previous studies that pretherapy subtype D infections are 'more aggressive' than subtype A1 by being associated with a lower baseline CD4 þ cell count [2, 3] . In terms of the relationship between HIV-1 subtype and viral tropism, our observation agrees with previous studies that subtype D is associated with a higher prevalence of non-R5-tropic viruses [7, 8, [11] [12] [13] [14] . In terms of the relationship between viral tropism and pretherapy CD4 þ cell count, our observation agrees with previous studies that non-R5 infections are associated with lower CD4 þ cell count [10, 27, 28] .
Unlike any of the aforementioned studies [2, 3, 7, 8, [10] [11] [12] [13] [14] 27, 28] that focused on only two factors at a time, we statistically examined the relationship between all three factors (subtype, tropism, and pretherapy CD4 þ cell count) by comparing baseline correlates and clinical outcomes between R5 infections in subtype A1 against D, as well as non-R5 infection in subtype A1 against D, and found no significant differences between groups. In other words, an infection that was both subtype D and non-R5 did not show a synergistic and negative effect at baseline when compared with subtype A non-R5 infections, suggesting that viral tropism, not subtype, drove the previously observed association between both non-R5 tropism, and subtype D with a lower pretherapy baseline CD4 þ cell count. Our multivariable linear regression model confirmed that the association between subtype D infections and a poorer pretherapy baseline CD4 þ cell count was attributed to tropism, but not to viral subtype, after adjusting for age, sex, and baseline viral load. A similar trend was reported in HIV-1 CRF01_AE compared to CRF07_BC and subtype B infections [29] .
The conclusion that pretherapy baseline CD4 þ cell count was associated with tropism not subtype was limited by the cross-sectional nature of this study and the lack of time since infection data, a factor strongly associated with CD4 þ depletion over time [30] . We cannot rule out that patients infected with non-R5 viruses were simply infected for a longer period of time and were at a more advanced disease stage than those infected with R5 viruses. The casual relationship between this commonly observed association between non-R5 viruses and advanced disease stage is still poorly understood [9] .
Another study limitation was the methods used for tropism and subtype prediction. It is possible that the reliability of genotypic tropism prediction algorithms like g2p is itself dependent on viral subtypes. We have previously reported that g2p with 5.75% fpr cutoff demonstrated lower sensitivity in subtype A1 (44.4%) and a lower specificity (68.2%) in subtype D viruses compared to subtype B (sensitivity 65.6%, specificity 90.5%) against Trofile phenotypic tropism assay, and other algorithms such as position-specific scoring matrices showed similar performance [24] . In the same study [24] , we also showed that adjusting the algorithms' cutoff value may further optimize sensitivity and specificity for each subtype. Hence, in the current study, we performed sensitivity analyses by redefining tropism with g2p cutoffs at 5, 10, 15, and 20%, and with a subtype-specific tropism inference tool PhenoSeq [25] ; overall, all yielded trends similar to our primary analysis with g2p cutoff at 5.75%.
In terms of subtype prediction, we have chosen RIP 3.0 with window size 400 among the myriad of subtype inferring tools available; these subtype prediction tools do not generate perfectly concordant results [31] . However, reanalyses using a more relaxed RIP window size of 100 as well as another HIV-1 subtyping tool REGA did not change our conclusions. Furthermore, we have demonstrated that using different parts of the HIV genome to infer subtype in the UARTO cohort introduced discordance because of a high prevalence of intragenome recombinants between subtypes. This problem was further explored in another study [32] . In this study, all intragene recombinants were excluded to avoid potential bias.
In conclusion, our study showed that pretherapy baseline CD4 þ cell count was associated with viral tropism, not subtype. We also showed that an overall 94% of study participants in this rural Ugandan cohort achieved virologic suppression within 3-month posttherapy, regardless of viral subtype or tropism, an indication that the HIV care architecture in this rural Ugandan village was highly effective.
